PHRR.F Stock Overview
A specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PharmaTher Holdings Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.17 |
| 52 Week High | CA$0.32 |
| 52 Week Low | CA$0.10 |
| Beta | 3.41 |
| 11 Month Change | 2.80% |
| 3 Month Change | 4.43% |
| 1 Year Change | 43.54% |
| 33 Year Change | -48.13% |
| 5 Year Change | n/a |
| Change since IPO | -8.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHRR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.1% | 1.6% | 2.2% |
| 1Y | 43.5% | 9.9% | 31.6% |
Return vs Industry: PHRR.F exceeded the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: PHRR.F exceeded the US Market which returned 31.6% over the past year.
Price Volatility
| PHRR.F volatility | |
|---|---|
| PHRR.F Average Weekly Movement | 16.1% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PHRR.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PHRR.F's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Fabio Chianelli | www.pharmather.com |
PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company’s product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson’s disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia and procedural sedation. It develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures.
PharmaTher Holdings Ltd. Fundamentals Summary
| PHRR.F fundamental statistics | |
|---|---|
| Market cap | US$15.51m |
| Earnings (TTM) | -US$1.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.4x
P/E RatioIs PHRR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHRR.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.16m |
| Earnings | -CA$2.16m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PHRR.F perform over the long term?
See historical performance and comparison